786
Views
17
CrossRef citations to date
0
Altmetric
Author's View

A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies

, , , , &
Article: e1022306 | Received 13 Jan 2015, Accepted 19 Feb 2015, Published online: 15 Jun 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Ieva Saulite, Desislava Ignatova, Yun-Tsan Chang, Christina Fassnacht, Florentia Dimitriou, Eleni Varypataki, Florian Anzengruber, Mirjam Nägeli, Antonio Cozzio, Reinhard Dummer, Julia Scarisbrick, Steve Pascolo, Wolfram Hoetzenecker, Malgorzata Bobrowicz & Emmanuella Guenova. (2020) Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. OncoImmunology 9:1.
Read now
Philippe Lefrançois, Pingxing Xie, Linghua Wang, Michael T. Tetzlaff, Linda Moreau, Andrew K. Watters, Elena Netchiporouk, Nathalie Provost, Martin Gilbert, Xiao Ni, Denis Sasseville, David A. Wheeler, Madeleine Duvic & Ivan V. Litvinov. (2018) Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. OncoImmunology 7:8.
Read now
Mauro Alaibac. (2017) Monoclonal antibodies against cutaneous T-cell lymphomas. Expert Opinion on Biological Therapy 17:12, pages 1503-1510.
Read now

Articles from other publishers (14)

Claudio Ortolani. 2021. Flow Cytometry of Hematological Malignancies. Flow Cytometry of Hematological Malignancies 301 427 .
Li Wang, Wei Qin, Yu-Jia Huo, Xiao Li, Qing Shi, John E. J. Rasko, Anne Janin & Wei-Li Zhao. (2020) Advances in targeted therapy for malignant lymphoma. Signal Transduction and Targeted Therapy 5:1.
Crossref
Malgorzata Bobrowicz, Radoslaw Zagozdzon, Joanna Domagala, Roberta Vasconcelos-Berg, Emmanuella Guenova & Magdalena Winiarska. (2019) Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives. Cancers 11:10, pages 1420.
Crossref
Vanessa Van-de-Velde & Youwen Zhou. (2019) Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma. Journal of Cutaneous Medicine and Surgery 23:3, pages 319-327.
Crossref
Katharina Leuchte, Max Schlaak, Rudolf Stadler, Sebastian Theurich & Michael von Bergwelt-Baildon. (2019) Innovative Behandlungskonzepte mit Modulation der Mikroumgebung beim kutanen T-Zell-Lymphom. Kompass Dermatologie 7:3, pages 111-119.
Crossref
Bethany Mundy-BosseNathan DenlingerEric McLaughlinNitin ChakravartiSusan HwangLi ChenHsiaoyin Charlene MaoDavid KlineYoussef Youssef, Rebecca KohnkenDean Anthony LeeGerard Lozanski, Aharon G. Freud, Pierluigi Porcu, Basem WilliamMichael A. CaligiuriAnjali Mishra. (2018) Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Advances 2:15, pages 1818-1827.
Crossref
Kazuyasu Fujii. (2018) New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma. Frontiers in Oncology 8.
Crossref
Brittany O. Dulmage, Betty Y. Kong, Kassandra Holzem & Joan Guitart. (2018) What Is New in CTCL—Pathogenesis, Diagnosis, and Treatments. Current Dermatology Reports 7:2, pages 91-98.
Crossref
Carlos Cuesta-Mateos, Ana Alcaraz-Serna, Beatriz Somovilla-Crespo & Cecilia Muñoz-Calleja. (2018) Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. Frontiers in Immunology 8.
Crossref
Lisa Argnani, Alessandro Broccoli & Pier Luigi Zinzani. (2017) Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. Cancer Treatment Reviews 61, pages 61-69.
Crossref
Charlotte Hurabielle, Nicolas Thonnart, Caroline Ram-Wolff, Hélène Sicard, Armand Bensussan, Martine Bagot & Anne Marie-Cardine. (2017) Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome. Clinical Cancer Research 23:14, pages 3619-3627.
Crossref
Yael Diesendruck & Itai Benhar. (2017) Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges. Drug Resistance Updates 30, pages 39-47.
Crossref
Rudolf Stadler. (2016) Das Sézary Syndrom - Neuste molekulare und immunologische Erkenntnisse. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 14:3, pages 225-227.
Crossref
Sima Rozati & Youn H. Kim. (2016) Experimental treatment strategies in primary cutaneous T-cell lymphomas. Current Opinion in Oncology 28:2, pages 166-171.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.